MX2015015163A - Derivados de imidazo-triazina como inhibidores de pde10. - Google Patents

Derivados de imidazo-triazina como inhibidores de pde10.

Info

Publication number
MX2015015163A
MX2015015163A MX2015015163A MX2015015163A MX2015015163A MX 2015015163 A MX2015015163 A MX 2015015163A MX 2015015163 A MX2015015163 A MX 2015015163A MX 2015015163 A MX2015015163 A MX 2015015163A MX 2015015163 A MX2015015163 A MX 2015015163A
Authority
MX
Mexico
Prior art keywords
imidazo
triazine derivatives
pde10 inhibitors
pde10
inhibitors
Prior art date
Application number
MX2015015163A
Other languages
English (en)
Spanish (es)
Inventor
Christopher John Helal
Patrick Robert Verhoest
Jamison Bryce Tuttle
Thomas Allen Chappie
Bethany Lyn Kormos
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2015015163A publication Critical patent/MX2015015163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2015015163A 2013-05-02 2014-04-23 Derivados de imidazo-triazina como inhibidores de pde10. MX2015015163A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361818650P 2013-05-02 2013-05-02
PCT/IB2014/060945 WO2014177977A1 (en) 2013-05-02 2014-04-23 Imidazo-triazine derivatives as pde10 inhibitors

Publications (1)

Publication Number Publication Date
MX2015015163A true MX2015015163A (es) 2016-02-22

Family

ID=50841902

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015163A MX2015015163A (es) 2013-05-02 2014-04-23 Derivados de imidazo-triazina como inhibidores de pde10.

Country Status (33)

Country Link
US (3) US8933224B2 (enExample)
EP (1) EP2991989B1 (enExample)
JP (1) JP6263606B2 (enExample)
KR (1) KR101770905B1 (enExample)
CN (1) CN105164134B (enExample)
AP (1) AP2015008843A0 (enExample)
AR (1) AR096161A1 (enExample)
AU (1) AU2014261070A1 (enExample)
BR (1) BR112015027760A8 (enExample)
CA (1) CA2910759C (enExample)
CL (1) CL2015003037A1 (enExample)
CR (1) CR20150591A (enExample)
CU (1) CU20150144A7 (enExample)
DK (1) DK2991989T3 (enExample)
DO (1) DOP2015000271A (enExample)
EA (1) EA027936B1 (enExample)
EC (1) ECSP15050110A (enExample)
ES (1) ES2637816T3 (enExample)
GE (1) GEP201706675B (enExample)
MA (1) MA38559B1 (enExample)
MD (1) MD20150103A2 (enExample)
MX (1) MX2015015163A (enExample)
NI (1) NI201500157A (enExample)
NZ (1) NZ712949A (enExample)
PE (1) PE20151940A1 (enExample)
PH (1) PH12015502462A1 (enExample)
SG (1) SG11201508201VA (enExample)
TN (1) TN2015000490A1 (enExample)
TW (1) TWI508966B (enExample)
UA (1) UA111696C2 (enExample)
UY (1) UY35547A (enExample)
WO (1) WO2014177977A1 (enExample)
ZA (1) ZA201508968B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
EP4059934B1 (en) 2016-09-09 2026-07-29 Novartis AG Compounds and compositions as inhibitors of endosomal toll-like receptors
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
KR20220087474A (ko) * 2019-10-21 2022-06-24 에스케이바이오팜 주식회사 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
WO2023150619A2 (en) * 2022-02-02 2023-08-10 The Katholieke Universiteit Leuven Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
CN117486878B (zh) * 2023-10-27 2026-05-05 扬州市普林斯医药科技有限公司 一种恩那司他的制备方法
CN121159397A (zh) * 2025-09-18 2025-12-19 江西芜锂增致循环科技有限公司 一种应用于高钠锂比卤水中提锂的硝基化β-双酮萃取剂的制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
TW200716102A (en) 2005-06-01 2007-05-01 Wyeth Corp Bicyclic 6-alkylidene-penems as class-D β -lactamases inhibitors
US20080051419A1 (en) 2006-07-26 2008-02-28 Pfizer Inc. Amine derivatives useful as anticancer agents
US8207370B2 (en) 2006-09-26 2012-06-26 Kaneka Corporation Process for producing optically active beta-hydroxy-alpha-aminocarboxylic acid ester
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
DE102007059723A1 (de) 2007-12-12 2009-06-18 Siemens Medical Instruments Pte. Ltd. Hörvorrichtung mit Batterieklappenmodul
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
PH12012500778A1 (en) * 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
US20130071415A1 (en) 2010-05-28 2013-03-21 Biocryst Pharmaceuticals, Inc. Heterocyclic Compounds as Janus Kinase Inhibitors
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
JP5543039B2 (ja) 2011-02-23 2014-07-09 ファイザー・インク 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン
MD20150103A2 (ro) * 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10

Also Published As

Publication number Publication date
CA2910759C (en) 2018-01-16
UY35547A (es) 2014-11-28
TW201506027A (zh) 2015-02-16
ES2637816T3 (es) 2017-10-17
US20150353579A1 (en) 2015-12-10
CL2015003037A1 (es) 2016-04-22
CR20150591A (es) 2016-01-04
CN105164134A (zh) 2015-12-16
US20150080401A1 (en) 2015-03-19
TWI508966B (zh) 2015-11-21
PH12015502462A1 (en) 2016-02-22
GEP201706675B (en) 2017-05-25
CU20150144A7 (es) 2016-04-25
NI201500157A (es) 2015-11-30
EA027936B1 (ru) 2017-09-29
US9145427B2 (en) 2015-09-29
EP2991989A1 (en) 2016-03-09
KR101770905B1 (ko) 2017-08-23
PE20151940A1 (es) 2016-01-21
NZ712949A (en) 2017-04-28
CN105164134B (zh) 2017-09-22
HK1213885A1 (zh) 2016-07-15
CA2910759A1 (en) 2014-11-06
US9296761B2 (en) 2016-03-29
BR112015027760A8 (pt) 2018-05-08
WO2014177977A1 (en) 2014-11-06
AU2014261070A1 (en) 2015-10-29
US20140329820A1 (en) 2014-11-06
DOP2015000271A (es) 2016-02-29
TN2015000490A1 (fr) 2017-04-06
MD20150103A2 (ro) 2016-02-29
SG11201508201VA (en) 2015-11-27
ZA201508968B (en) 2017-11-29
MA38559B1 (fr) 2018-04-30
EP2991989B1 (en) 2017-06-28
UA111696C2 (uk) 2016-05-25
JP6263606B2 (ja) 2018-01-17
DK2991989T3 (en) 2017-07-31
US8933224B2 (en) 2015-01-13
EA201591819A1 (ru) 2016-05-31
ECSP15050110A (es) 2017-08-31
JP2016517877A (ja) 2016-06-20
AR096161A1 (es) 2015-12-09
KR20160003234A (ko) 2016-01-08
AP2015008843A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
PH12017500408A1 (en) Heteroaryl compunds as btk inhibitors and uses thereof
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
PH12015500263A1 (en) New bicyclic derivatives
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
PH12015501843A1 (en) Novel pyrazol derivatives
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
JO3318B1 (ar) مثبطات bace
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
MY180050A (en) Novel purine derivatives
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2015013374A (es) Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag).
MX363458B (es) Nuevos derivados de tetrazolona.
MX2015011005A (es) Derivados de dihidorquinolin-2-ona para usarse como inhibidores de aldoesterona sintasa.
MX2016006807A (es) Derivados de imidazol.
MX2015009377A (es) Compuestos radiomarcados.
JO3298B1 (ar) مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
IN2012DE00110A (enExample)
MX2016002762A (es) Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa.